From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
FKBP12 PROTAC dTAG-13 (dTAG-13), a PROTAC-based heterobifunctional degrader, is a selective degrader of FKBP12 F36V with expression of FKBP12F36V in-frame with a protein of interest. FKBP12 PROTAC dTAG-13 effectively engages FKBP12 F36V and CRBN, thereby selectively degrading FKBP12 F36V .
FKBP12 PROTAC dTAG-7 (dTAG-7) is a heterobifunctional degrader. FKBP12 PROTAC dTAG-7 (dTAG-7) is a degrader of FKBP12 F36V with expression of FKBP12 F36V in-frame with a protein of interest. FKBP12 PROTAC dTAG-7 (dTAG-7) also is a selective degrader of BET bromodomain transcriptional co-activator BRD4 by bridging BET bromodomains to an E3 ubiquitin ligase CRBN .
FKBP51-Hsp90-IN-2 (Compound E08) is a selective FKBP51-Hsp90 protein-protein interaction inhibitor with IC50 values of 0.4 µM and 5 µM for FKBP51 and FKBP52, respectively. FKBP51-Hsp90-IN-2 also effectively stimulates cellular energy metabolism and neurite growth. FKBP51-Hsp90-IN-2 can be used in research on neurodegenerative diseases and cancer .
FKBP51-Hsp90-IN-1 (Compound D10) is a selective inhibitor of the FKBP51-Hsp90 protein-protein interaction, with an IC50 value of 0.1 μM against FKBP51. FKBP51-Hsp90-IN-1 can be used in the research of stress-related diseases, Alzheimer's disease, and metabolic disorders .
FKBP51F67V-selective antagonist Ligand2 (example 3-3) is a potent FKBP51 F67V-selective antagonist ligand. FKBP51F67V-selective antagonist Ligand2 reverses the anxiogenic phenotype induced by overexpression of FKBP51 F67V in the amygdala. FKBP51F67V-selective antagonist Ligand2 binds to FKBP51 F67V, but not to wild-type FKBP51 or FKBP52 .
FKBP12 PROTAC RC32 (RC32) is a potent FKBP12 degrader based on PROTAC technology. FKBP12 PROTAC RC32 contains conjugation of Rapamycin (HY-10219) and a ligand for an Cereblon E3 ubiquitin ligase (Pomalidomide; HY-10984) .
FKBP10 Human Pre-designed siRNA Set A contains three designed siRNAs for FKBP10 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
FKBP11 Human Pre-designed siRNA Set A contains three designed siRNAs for FKBP11 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
FKBP14 Human Pre-designed siRNA Set A contains three designed siRNAs for FKBP14 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
FKBP15 Human Pre-designed siRNA Set A contains three designed siRNAs for FKBP15 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
FKBP2 Human Pre-designed siRNA Set A contains three designed siRNAs for FKBP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
FKBP3 Human Pre-designed siRNA Set A contains three designed siRNAs for FKBP3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
FKBP4 Human Pre-designed siRNA Set A contains three designed siRNAs for FKBP4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
FKBP5 Human Pre-designed siRNA Set A contains three designed siRNAs for FKBP5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
FKBP6 Human Pre-designed siRNA Set A contains three designed siRNAs for FKBP6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
FKBP7 Human Pre-designed siRNA Set A contains three designed siRNAs for FKBP7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
FKBP8 Human Pre-designed siRNA Set A contains three designed siRNAs for FKBP8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
FKBP9 Human Pre-designed siRNA Set A contains three designed siRNAs for FKBP9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
FKBP1A Human Pre-designed siRNA Set A contains three designed siRNAs for FKBP1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
FKBP1B Human Pre-designed siRNA Set A contains three designed siRNAs for FKBP1B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
PROTAC FKBP Degrader-3 is a PROTAC that comprises a FKBP ligand binding group, a linker and an von Hippel-Lindau binding group. PROTAC FKBP Degrader-3 is a potent FKBP degrader .
SLF is a synthetic ligand for FK506-binding protein (FKBP) with an affinity of 3.1 μM for FKBP51 and an IC50 of 2.6 μM for FKBP12. SLF can be used in the synthesis of PROTAC .
SLF TFA is a synthetic ligand for FK506-binding protein (FKBP) with an affinity of 3.1 μM for FKBP51 and an IC50 of 2.6 μM for FKBP12. SLF TFA can be used in the synthesis of PROTAC .
SLF-amido-C2-COOH (PROTAC FKBP12-binding moiety 1) is a synthetic ligand for FKBP (SLF). SLF-amido-C2-COOH (PROTAC FKBP12-binding moiety 1) can be used in the synthesis of PROTACs .
AP1867-2-(carboxymethoxy), the AP1867 (a synthetic FKBP12 F36V-directed ligand) based moiety, binds to CRBN ligand via a linker to form dTAG molecules .
AUTAC2 is a FKBP12-targeting autophagy-mediated degrader (AUTAC). AUTAC2 contains an FBnG (p-Fluorobenzyl Guanine) and an SLF (c ligand of FKBP) moiety. SLF binds non-covalently to FKBP12 .
Shield-1 (Shld1) is a specific, cell-permeant and high-affinity ligand of FK506-binding protein-12 (FKBP), and reverses the instability by binding to mutated FKBP (mtFKBP), allowing conditional expression of mtFKBP-fused proteins. Shield-1 can stabilize proteins tagged with a mutated FKBP12-derived destabilization domain (DD) .
dTAG-47, heterobifunctional dTAG molecule, targets mutant FKBP12 (FKBP12 F36V). FKBP12 F36V serves as a degradation tag (dTAG) and is fused to a protein of interest. dTAG-47 can be used for the research of basal-like breast cancers (BBC) .
dFKBP-1 is a potent and PROTAC-based FKBP12 degrader. dFKBP-1 incorporates the ligand SLF (HY-114872) of FKBP12, the Thalidomide based Cereblon ligand and a linker .
ILS-920 is a nonimmunosuppressive Rapamycin analog with reduced immunosuppressive activity and potent neuroprotective activity. ILS-920 binds selectively to the immunophilin FKBP52 and to the β1-subunit of L-type voltage-gated calcium channels (VGCC). ILS-920 shows 200-fold selectivity for FKBP52 versus FKBP12 .
TSPO ligand-3 is a ligand of AUTAC2. AUTAC2 contains an p-fluorobenzylguanine (FBnG) and an synthetic ligand of FKBP (SLF) moiety, which can cause significant silencing of FKBP12 in HeLa cells .
AP1867-3-(aminoethoxy), the AP1867 based moiety, is a synthetic ligand for FKBP. AP1867-3-(aminoethoxy) can be used in the synthesis of PROTAC FKBP12 F36V degrader .
dTAG-13-NEG is a negative control of dTAG-13. dTAG-13 (HY-114421), a PROTAC-based heterobifunctional degrader, is a selective degrader of FKBP12 F36V with expression of FKBP12F36V in-frame with a protein of interest .
Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .
Everolimus-d4 is the deuterium labeled Everolimus. Everolimus (RAD001) is a Rapamycin derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities[1][2].
mTORC1-IN-1 (T1) is a rapamycin homologue (rapalog) and selective mTORC1 inhibitor. mTORC1-IN-1 regulates cell growth and metabolism and is implicated in a variety of diseases including cancer. mTORC1-IN-1 targets mTORC1 by binding to the FKBP12-FRB complex (docking score = −11.6 kcal/mol) .
Everolimus (Standard) is the analytical standard of Everolimus. This product is intended for research and analytical applications. Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .
Rimiducid (AP1903) is a dimerizer agent that acts by cross-linking the FKBP domains. Rimiducid (AP1903) dimerizes the Caspase 9 suicide switch and rapidly induces apoptosis.
ElteN378 is an inhibitors of FKBP12e. ElteN378 can be used in study Alzheimer disease, Parkinson disease, Amyotrophic Lateral Sclerosis, proliferation disorders and cancer .
KB02-SLF is a PROTAC-based nuclear FKBP12 degrader (molecular glue). KB02-SLF promotes nuclear FKBP12 degradation by covalently modifying DCAF16 (E3 ligase) and can improve the durability of protein degradation in biological systems. SLF binds ubiquitin E3 ligase ligand KB02 via a linker to form KB02-SLF .
mTOR inhibitor-8 is an mTOR inhibitor and autophagy inducer. mTOR inhibitor-8 inhibits the activity of mTOR via FKBP12 and induces autophagy of A549 human lung cancer cells .
AP20187 (B/B Homodimerizer) is a cell-permeable ligand used to dimerize FK506-binding protein(FKBP) fusion proteins and initiate biological signaling cascades and gene expression or disrupt protein-protein interactions.
Tacrolimus monohydrate (FK506 monohydrate), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex and inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties .
Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .
Tacrolimus (FK506), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties .
Thalidomide-4-O-C6-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate used in the PROTAC dTAG-13, a degrader of FKBP12 F36V and BET .
Zapalog is a photocleavable small-molecule heterodimerizer that can be used to repeatedly initiate, and instantaneously terminate, a physical interaction between two target proteins. Zapalog dimerizes any two proteins tagged with the FKBP and DHFR domains until exposure to light causes its photolysis .
Thalidomide-4-O-C6-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate used in the PROTAC dTAG-13 (HY-114421), a degrader of FKBP12 F36V and BET .
Rapamycin-d3 is the deuterium labeled Rapamycin. Rapamycin is a potent and specific mTOR inhibitor with an IC50of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].
Tacrolimus- 13C,d2 is a 13C-labeled and deuterium labeled Tacrolimus. Tacrolimus (FK506), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties[1].
Rapamycin- 13C,d3 (Sirolimus- 13C,d3; AY-22989- 13C,d3) is the 13C and deuterium labeled Rapamycin (HY-10219) . Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .
RapaLink-1, the third-generation bivalent mTOR inhibitor, combines Rapamycin (HY-10219) with MLN0128 (HY-13328, a second-generation mTOR kinase inhibitor) by an inert chemical linker. RapaLink-1 shows better efficacy than Rapamycin or mTOR kinase inhibitors (TORKi), potently blocking cancer-derived, activating mutants of mTOR. RapaLink-1 can cross the blood-brain barrier. RapaLink-1 binding to FKBP12 results in targeted and durable inhibition of mTORC1. RapaLink-1 plays an antithrombotic role in antiphospholipid syndrome by improving autophagy. Anticancer activity .
Tacrolimus monohydrate (FK506 monohydrate), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex and inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties .
Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .
Tacrolimus (FK506), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties .
The FKBP14 protein is a peptidyl prolyl cis-trans isomerase (PPIase) that uniquely accelerates protein folding, particularly in protein synthesis. FKBP14 particularly favors 4-hydroxyproline-modified substrates, exhibits significant affinity for type III collagen, and has potential effects on type VI and type X collagen. FKBP14 Protein, Human (HEK293, His) is the recombinant human-derived FKBP14 protein, expressed by HEK293 , with C-His labeled tag. The total length of FKBP14 Protein, Human (HEK293, His) is 188 a.a., with molecular weight of ~25 & 27 kDa, respectively.
The FKBP11 protein is a peptidyl prolyl cis-trans isomerase (PPIase) that plays a crucial role in accelerating protein folding, especially in complex protein synthesis. FKBP11 uses its enzymatic abilities to promote rapid and precise conformational changes that are critical for correct protein folding and maturation. FKBP11 Protein, Human (HEK293, Fc) is the recombinant human-derived FKBP11 protein, expressed by HEK293 , with C-mFc labeled tag. The total length of FKBP11 Protein, Human (HEK293, Fc) is 128 a.a., with molecular weight of ~40.4-45 KDa.
FKBP12 protein maintains TGFBR1 in an inactive state, inhibits activin signaling by recruiting SMAD7, and modulates RYR1 calcium channel activity. As a PPIase, it speeds up protein folding. FKBP12's multifunctionality underscores its regulatory role in cellular processes, emphasizing its importance in signaling and protein folding. FKBP12 Protein, Human (His) is the recombinant human-derived FKBP12 protein, expressed by E. coli , with C-His labeled tag. The total length of FKBP12 Protein, Human (His) is 108 a.a., with molecular weight of ~12.9 KDa.
The FKBP12 protein is multifunctional and critical in TGF-β signaling by maintaining TGFBR1 in an inactive conformation, thereby preventing receptor activation in the absence of ligand. It recruits SMAD7 to ACVR1B, blocks the binding of SMAD2 and SMAD3 to the activin receptor complex, and thereby inhibits activin signaling. FKBP12 Protein, Mouse (His) is the recombinant mouse-derived FKBP12 protein, expressed by E. coli , with N-His labeled tag. The total length of FKBP12 Protein, Mouse (His) is 107 a.a., with molecular weight of ~13 KDa.
FKBP3 is a member of the FK506 and rapamycin-binding protein (FKBP) family and serves as a receptor for the immunosuppressants FK506 and rapamycin, both of which inhibit two distinct cytoplasmic signaling pathways. T cell proliferation. In addition to serving as a receptor for these immunosuppressants, FKBP3, like other peptidyl prolyl cis-trans isomerases (PPIases), also functions to accelerate protein folding. FKBP3 Protein, Human (His) is the recombinant human-derived FKBP3 protein, expressed by E. coli , with N-6*His labeled tag. The total length of FKBP3 Protein, Human (His) is 224 a.a., with molecular weight of ~30.0 kDa.
The FKBP7 protein is a peptidyl prolyl cis-trans isomerase (PPIase) that significantly accelerates protein folding, especially in the complexities of protein synthesis. Utilizing its enzymatic abilities, FKBP7 plays a crucial role in coordinating timely conformational changes to achieve correct protein folding and maturation. FKBP7 Protein, Human (199a.a, HEK293, His) is the recombinant human-derived FKBP7 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of FKBP7 Protein, Human (199a.a, HEK293, His) is 199 a.a., with molecular weight of 25-32 kDa.
The FKBP4 protein is an immunophilin with peptidyl prolyl cis-trans isomerase (PPIase) and co-chaperone activity. It plays a key role in the formation of hybrids with steroid receptors, specifically by interacting with heat shock protein 90 (HSP90). FKBP4 Protein, Human (His) is the recombinant human-derived FKBP4 protein, expressed by E. coli , with C-6*His labeled tag. The total length of FKBP4 Protein, Human (His) is 459 a.a., with molecular weight of 50-60 kDa.
FKBP2 protein plays a central role in the complex process of protein folding and is an important peptidyl prolyl cis-trans isomerase (PPIase). Its unique ability to catalyze the cis-trans isomerization of proline imide peptide bonds accelerates dynamic conformational changes that are critical for efficient protein folding. FKBP2 Protein, Human (HEK293, His) is the recombinant human-derived FKBP2 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of FKBP2 Protein, Human (HEK293, His) is 121 a.a., with molecular weight of ~17.0 kDa.
FKBP7 Protein, a peptidyl-prolyl cis-trans isomerase (PPIase), significantly expedites protein folding, especially in the complexity of protein synthesis. Leveraging its enzymatic prowess, FKBP7 plays a crucial role in orchestrating timely conformational changes for proper protein folding and maturation. As a member of the PPIase family, FKBP7 adeptly catalyzes cis-trans isomerization, influencing structural dynamics in polypeptides. This highlights FKBP7's pivotal role in maintaining cellular protein homeostasis and underscores its potential impact on cellular physiology, urging further exploration of its specific molecular mechanisms in protein folding during synthesis. FKBP7 Protein, Human (HEK293, Fc) is the recombinant human-derived FKBP7 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of FKBP7 Protein, Human (HEK293, Fc) is 218 a.a., with molecular weight of ~55 kDa.
FKBP7 Protein, a peptidyl-prolyl cis-trans isomerase (PPIase), significantly expedites protein folding, especially in the complexity of protein synthesis. Leveraging its enzymatic prowess, FKBP7 plays a crucial role in orchestrating timely conformational changes for proper protein folding and maturation. As a member of the PPIase family, FKBP7 adeptly catalyzes cis-trans isomerization, influencing structural dynamics in polypeptides. This highlights FKBP7's pivotal role in maintaining cellular protein homeostasis and underscores its potential impact on cellular physiology, urging further exploration of its specific molecular mechanisms in protein folding during synthesis. FKBP7 Protein, Human (218a.a, HEK293, His) is the recombinant human-derived FKBP7 protein, expressed by HEK293 , with C-His labeled tag. The total length of FKBP7 Protein, Human (218a.a, HEK293, His) is 218 a.a., with molecular weight of ~27 & 30 kDa, respectively.
The FkpA protein plays a central role in cellular processes, acting as a key catalyst in the complex dance of protein folding. Its catalytic efficiency is excellent in promoting the cis-trans isomerization of proline-imine peptide bonds, thus accelerating the overall folding of proteins. FkpA Protein, E.coli (His-SUMO) ) is the recombinant E. coli-derived FkpA protein, expressed by E. coli , with N-His, N-SUMO labeled tag.
Rapamycin-d3 is the deuterium labeled Rapamycin. Rapamycin is a potent and specific mTOR inhibitor with an IC50of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].
Tacrolimus- 13C,d2 is a 13C-labeled and deuterium labeled Tacrolimus. Tacrolimus (FK506), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties[1].
Everolimus-d4 is the deuterium labeled Everolimus. Everolimus (RAD001) is a Rapamycin derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities[1][2].
Rapamycin- 13C,d3 (Sirolimus- 13C,d3; AY-22989- 13C,d3) is the 13C and deuterium labeled Rapamycin (HY-10219) . Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .
FKBP12 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 12 kDa, targeting to FKBP12. It can be used for WB,ICC/IF assays with tag free, in the background of Human, Mouse.
FKBP51 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 51 kDa, targeting to FKBP51. It can be used for WB,IHC-P,IP,FC assays with tag free, in the background of Human, Rat.
FKBP52 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 52 kDa, targeting to FKBP52. It can be used for WB,ICC,IHC-P,FC assays with tag free, in the background of Human, Mouse.
MTOR; FRAP; FRAP1; FRAP2; RAFT1; RAPT1; Serine/threonine-protein kinase mTOR; FK506-binding protein 12-rapamycin complex-associated protein 1; FKBP12-rapamycin complex-associated protein; Mammalian target of rapamycin; mTOR; Mechanistic tar
WB, IHC-P, ICC/IF, IP, FC
Human, Mouse, Rat
mTOR Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 289 kDa, targeting to mTOR. It can be used for WB,IHC-P,ICC/IF,IP,FC assays with tag free, in the background of Human, Mouse, Rat.
MTOR; FRAP; FRAP1; FRAP2; RAFT1; RAPT1; Serine/threonine-protein kinase mTOR; FK506-binding protein 12-rapamycin complex-associated protein 1; FKBP12-rapamycin complex-associated protein; Mammalian target of rapamycin; mTOR; Mechanistic tar
WB
Human, Mouse, Rat
Phospho-mTOR (Ser2481) Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 289 kDa, targeting to Phospho-mTOR (Ser2481). It can be used for WB assays with tag free, in the background of Human, Mouse, Rat.
MTOR; FRAP; FRAP1; FRAP2; RAFT1; RAPT1; Serine/threonine-protein kinase mTOR; FK506-binding protein 12-rapamycin complex-associated protein 1; FKBP12-rapamycin complex-associated protein; Mammalian target of rapamycin; mTOR; Mechanistic tar
WB, IHC-P
Human, Mouse
Phospho-mTOR (Ser2448) Antibody (YA171) is a non-conjugated and Rabbit origined monoclonal antibody about 289 kDa, targeting to Phospho-mTOR (Ser2448). It can be used for WB,IHC-P assays with tag free, in the background of Human, Mouse.
Inquiry Online
Your information is safe with us. * Required Fields.